1 /8

RECEIVED CENTRAL FAX CENTER

APR 0 5 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United State	es Patent Application of:) Docket No.:	4115-194
Applicants:	PAUZA, C. David, et al.) Conf. No.:	7524
Application No.:	10/539,677) Art Unit:	1614
Date Filed:	June 16, 2005	Examiner:	Not Yet Assigned
Title:	VACCINES AGAINST HIV-1 TAT PROTEIN TO GENERATE NEUTRALIZING ANTIBODIES	Customer No.: Customer No.: Customer No.:	23448

FACSIMILE TRANSMISSION CERTIFICATE

Fax No. (571) 273-8300

I hereby certify that this document, along with any enclosure(s) identified herein, is being filed in the United States Platent and Trademark Office, via facsimile transmission to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date specified below, to United States Patent and Trademark Office facsimile transmission number (571) 1273-830.

8	
Number of Pages (including cover)	
Marin Stryptzak Karin Stryptzak	
/ Karin Skypezak /	
April 5, 2006	
Date	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN U.S. PATENT APPLICATION NO. 10/539,677

4115-194

2 /8

Mail Stop Amendment Commissioner for Patents P.O: Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of the nonpatent reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Supplemental Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted

Steven J. Hultquist Reg. No. 28,021 Attorney for Applicants

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW Phone: (919) 419-9350 Fax: (919) 419-9354 Attorney File No.: 4115-194

Enclosures: IDS Form [1 pg.] Nonpatent Reference [5 pgs.]

The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284

3 /8

PTO/SB/08a (07-05) Approved for use through 07/31/2008. CMB 0851-0331

Under t	he Paperwork Reduction Act of 1995, n	o persor	ns are required to r	respond to a collection of informa	tion unless it displays a valid OMB control number.	
	Substitute for form 1449A/PTO			Complete if Known		
Sub				Application Number	10/539,677	
16	NFORMATION DISCL	OS.	IIDE	Filing Date	6/16/2005	
				First Named Inventor	Pauza et al.	
3	STATEMENT BY APPLICANT (Use as many sheets as necessary)		ANT	Art Unit	1614	
			Examiner Name	Not yet assigned		
Sheet	1	of	1 '	Attorney Docket Number	4115-194	

			U.S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number - Kind Code ^{2 (Finance}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.H./	CI	US- 6,193,981 B1	02-27-2001	Goldstein, Gideon	
7L.H./	Cl	US- 5,656,480 A	08-12-1997	Wild, Carl T., et al.	
		US-			

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T	
/L.H./	СК	LUO, LIZHONG, ET AL., Chimeric gog-V3 virus-like particles of human immunodeficiency virus induce virus- neutralizing antibodies, <i>Proc. Netl. Acad. Sci.</i> USA, November 1, 1992, Page(s) 10527-10531, Volume 89, Number 21.		
			T	
			t	
	-		H	
- 1			l	

Examiner	/Louise Humphrey/	Date	04/15/2008
Signature		Considered	
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609	Dow line throu	th citation if not in conformance and not

"EXAMINE: hital if reference considend, whether or not clastice is in concileration with MEPS 0.00 (Insert the through clastion if not in concileration classice) considered, include copy of his form with next communication be applicant. Floridant's undependent considered (classice) copy of his form with next communication be applicant. Placeful form of the comment of the document, by the body of copiesting. See official states of the comment of the com

Infrastruction alsophored. Integrated by 27 CFR 187 and 188. The Information is required to obtain or retain a benefit by the public which is to file (and by the Difference of Infrastructure o

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.